Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: A safety report

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 702-709

  Okines, A F C ^a   Langley, R E ^b   Thompson, L C ^b   Stenning, S P ^b   Stevenson, L ^b   Falk, S ^c   Seymour, M ^d   Coxon, F ^e   Middleton, G W ^f   Smith, D ^g   Evans, L ^h   Slater, S ⁱ   Waters, J ^j   Ford, D ^k   Hall, M ^l   Iveson, T J ^m   Petty, R D ⁿ   Plummer, C ^e   Allum, W H ^a   Blazeby, J M ^o   Griffin, M ^p   Cunningham, D ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

^f ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^g CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^h WESTON PARK HOSPITAL   (United Kingdom)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^j MAIDSTONE HOSPITAL   (United Kingdom)

^k QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^l WEXHAM PARK HOSPITAL   (United Kingdom)

^m UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁿ ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^o UNIVERSITY OF BRISTOL   (United Kingdom)

^p ROYAL VICTORIA INFIRMARY   (United Kingdom)

more..

Author keywords

Adenocarcinoma; Bevacizumab; Chemotherapy; Gastric; Oesophagus; Peri operative

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; EPIRUBICIN;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANASTOMOSIS LEAKAGE; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CARCINOMA; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; TASTE; THORAX PAIN; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING; WOUND COMPLICATION; WOUND HEALING; WOUND INFECTION;

EID: 84874570041     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds533     Document Type: Article

References (28)

1. Cunningham D, Allum WH, Stenning SP et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
2. Ychou M, Boige V, Pignon JP et al.. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721.
3. Ohtsu A, Shah MA, Van Cutsem E et al.. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976.
4. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305: 487-494.
5. Ranpura V, Hapani S, Chuang J et al.. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49: 287-297.
6. Choueiri TK, Mayer EL, Je Y et al.. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011.
7. Wedam SB, Low JA, Yang SX et al.. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
8. D'Adamo DR, Anderson SE, Albritton K et al.. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135-7142.
9. Lang RM, Bierig M, Devereux RB et al.. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
10. Kozloff M, Yood MU, Berlin J et al.. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
11. Saltz LB, Clarke S, Diaz-Rubio E et al.. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
12. Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
13. Giantonio BJ, Catalano PJ, Meropol NJ et al.. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
14. Hochster HS, Hart LL, Ramanathan RK et al.. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008; 26: 3523-3529.
15. Allegra CJ, Yothers G, O'Connell MJ et al.. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385-3390.
16. Nalluri SR, Chu D, Keresztes R et al.. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
17. Starling N, Rao S, Cunningham D et al.. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
18. Shah MA, Ramanathan RK, Ilson DH et al.. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206.
19. Shah MA, Jhawer M, Ilson DH et al.. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29: 868-874.
20. von Minckwitz G, Eidtmann H, Rezai M et al.. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
21. Scappaticci FA, Fehrenbacher L, Cartwright T et al.. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180.
22. Allegra CJ, Yothers G, O'Connell MJ et al.. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2010; 29: 11-16.
23. De Gramont A, Van Cutsem E, Tabernero J et al.. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 vs. FOLFOX4 alone as adjuvant treatment forcolon cancer. In Gastrointestinal Symposium, Edition San Francisco: 2011; Abstract number 362.
24. Ebos JM, Lee CR, Cruz-Munoz W et al.. ;Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell;2009; 15, 232-239
25. Burger RA, Brady MF, Bookman MA et al.. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483. 26. Perren TJ, Swart AM, Pfisterer J et al.. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
26. Perren TJ, Swart AM, Pfisterer J et al.. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
27. Allum WH, Stenning SP, Bancewicz J et al.. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009,27: 5062-5067.
28. Kelsen DP, Winter KA, Gunderson LL et al.. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007 25;3719-3725